CIMT 2013

References

• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480 - 9; http://dx.doi.org/10.1038/nature10673; PMID: 22193102
   PubMed Web of Science ®Google Scholar
• Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924 - 7; http://dx.doi.org/10.1126/science.1122927; PMID: 16484453
   PubMed Web of Science ®Google Scholar
• Prlic M, Bevan MJ. Immunology. An antibody paradox, resolved. Science 2006; 311:1875 - 6; http://dx.doi.org/10.1126/science.1126030; PMID: 16574856
   PubMed Web of Science ®Google Scholar
• Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010; 107:11906 - 11; http://dx.doi.org/10.1073/pnas.1002569107; PMID: 20547866
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kühn U, Müller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135 - 42; http://dx.doi.org/10.1002/eji.1830271209; PMID: 9464798
   PubMed Web of Science ®Google Scholar
• Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 2007; 5:18; http://dx.doi.org/10.1186/1479-5876-5-18; PMID: 17430585
   PubMed Web of Science ®Google Scholar
• Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010; 185:738 - 47; http://dx.doi.org/10.4049/jimmunol.1000060; PMID: 20511554
   PubMed Web of Science ®Google Scholar
• Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med 2010; 8:90; http://dx.doi.org/10.1186/1479-5876-8-90; PMID: 20920165
   PubMed Web of Science ®Google Scholar
• Spranger S, Frankenberger B, Schendel DJ. NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med 2012; 10:30; http://dx.doi.org/10.1186/1479-5876-10-30; PMID: 22364226
   PubMed Web of Science ®Google Scholar
• Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, et al. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol 2012; 189:598 - 605; http://dx.doi.org/10.4049/jimmunol.1102165; PMID: 22689880
   PubMed Web of Science ®Google Scholar
• Wilde S, Schendel DJ. High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find them. Oncoimmunology 2012; 1:1643 - 4; http://dx.doi.org/10.4161/onci.21717; PMID: 23264922
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; http://dx.doi.org/10.1038/nm.2883; PMID: 22842478
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med 2013; 19:465 - 72; http://dx.doi.org/10.1038/nm.3105; PMID: 23455713
   PubMed Web of Science ®Google Scholar
• Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, et al. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:72ra20; http://dx.doi.org/10.1126/scitranslmed.3004888; PMID: 23408053
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709 - 20; http://dx.doi.org/10.1182/blood-2011-10-384388; PMID: 22160384
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; http://dx.doi.org/10.1126/scitranslmed.3002842; PMID: 21832238
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817 - 28; http://dx.doi.org/10.1182/blood-2011-04-348540; PMID: 21849486
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:77ra38; http://dx.doi.org/10.1126/scitranslmed.3005930; PMID: 23515080
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133 - 41; http://dx.doi.org/10.1182/blood-2011-12-400044; PMID: 22354001
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One 2013; 8:e64138; http://dx.doi.org/10.1371/journal.pone.0064138; PMID: 23741305
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116; PMID: 21498393
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12:671 - 84; http://dx.doi.org/10.1038/nrc3322; PMID: 22996603
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J Immunother 2012; 35:651 - 60; http://dx.doi.org/10.1097/CJI.0b013e31827806e6; PMID: 23090074
   PubMed Web of Science ®Google Scholar
• McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, McDuffie M, et al. Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 2008; 26:1863 - 73; http://dx.doi.org/10.1016/j.vaccine.2008.01.052; PMID: 18329760
   PubMed Web of Science ®Google Scholar
• Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, et al. TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother 2012; 61:1627 - 38; http://dx.doi.org/10.1007/s00262-012-1217-5; PMID: 22350070
   PubMed Web of Science ®Google Scholar
• Buhrman JD, Jordan KR, U’ren L, Sprague J, Kemmler CB, Slansky JE. Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res 2013; 73:74 - 85; http://dx.doi.org/10.1158/0008-5472.CAN-12-1005; PMID: 23161490
   PubMed Web of Science ®Google Scholar
• Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006; 66:5427 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-06-0399; PMID: 16707471
   PubMed Web of Science ®Google Scholar
• Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res 2009; 69:6265 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-09-0579; PMID: 19622767
   PubMed Web of Science ®Google Scholar
• Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412 - 6; http://dx.doi.org/10.1038/nature11538; PMID: 23051752
   PubMed Web of Science ®Google Scholar
• Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466:133 - 7; http://dx.doi.org/10.1038/nature09161; PMID: 20596026
   PubMed Web of Science ®Google Scholar
• Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. Nat Rev Cancer 2013; 13:365 - 76; http://dx.doi.org/10.1038/nrc3498; PMID: 23535846
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658 - 70; http://dx.doi.org/10.1038/nbt.2287; PMID: 22781695
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329 - 36; http://dx.doi.org/10.1038/nm.3089; PMID: 23396206
   PubMed Web of Science ®Google Scholar
• Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011; 19:1913 - 22; http://dx.doi.org/10.1038/mt.2011.132; PMID: 21772252
   PubMed Web of Science ®Google Scholar
• Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 18:1430 - 9; http://dx.doi.org/10.1038/mt.2010.98; PMID: 20551919
   PubMed Web of Science ®Google Scholar
• Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009; 81:6813 - 22; http://dx.doi.org/10.1021/ac901049w; PMID: 19601617
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046 - 54; http://dx.doi.org/10.1200/JCO.2011.38.4032; PMID: 22547592
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690; PMID: 20388795
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19:57 - 64; http://dx.doi.org/10.1038/nm.2999; PMID: 23202296
   PubMed Web of Science ®Google Scholar
• Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013; 104:43 - 7; http://dx.doi.org/10.1111/cas.12027; PMID: 23004020
   PubMed Web of Science ®Google Scholar
• de León J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008; 20:591 - 600; http://dx.doi.org/10.1093/intimm/dxn018; PMID: 18310617
   PubMed Web of Science ®Google Scholar
• Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37:533 - 46; http://dx.doi.org/10.1053/j.seminoncol.2010.09.015; PMID: 21074069
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388 - 97; http://dx.doi.org/10.1093/jnci/djq310; PMID: 20826737
   PubMed Web of Science ®Google Scholar
• Prendergast GC. Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. Oncoimmunology 2012; 1:793 - 7; http://dx.doi.org/10.4161/onci.20909; PMID: 23162746
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, et al. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 2010; 59:1655 - 63; http://dx.doi.org/10.1007/s00262-010-0891-4; PMID: 20640572
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2:722 - 35; http://dx.doi.org/10.1158/2159-8290.CD-12-0014; PMID: 22822050
   PubMed Web of Science ®Google Scholar
• Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 2012; 1:1460 - 8; http://dx.doi.org/10.4161/onci.21716; PMID: 23264892
   PubMed Web of Science ®Google Scholar
• Graham GJ, Locati M, Mantovani A, Rot A, Thelen M. The biochemistry and biology of the atypical chemokine receptors. Immunol Lett 2012; 145:30 - 8; http://dx.doi.org/10.1016/j.imlet.2012.04.004; PMID: 22698181
   PubMed Web of Science ®Google Scholar
• Borroni EM, Cancellieri C, Vacchini A, Benureau Y, Lagane B, Bachelerie F, et al. β-arrestin-dependent activation of the cofilin pathway is required for the scavenging activity of the atypical chemokine receptor D6. Sci Signal 2013; 6:1 - 11, S1-3; http://dx.doi.org/10.1126/scisignal.2003627; PMID: 23633677
   PubMed Web of Science ®Google Scholar
• Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012; 2:628 - 39; http://dx.doi.org/10.1016/j.celrep.2012.08.006; PMID: 22959433
   PubMed Web of Science ®Google Scholar
• Sonda N, Simonato F, Peranzoni E, Calì B, Bortoluzzi S, Bisognin A, et al. miR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. Immunity 2013; 38:1236 - 49; http://dx.doi.org/10.1016/j.immuni.2013.06.004; PMID: 23809164
   PubMed Web of Science ®Google Scholar
• Mildner A, Chapnik E, Manor O, Yona S, Kim KW, Aychek T, et al. Mononuclear phagocyte miRNome analysis identifies miR-142 as critical regulator of murine dendritic cell homeostasis. Blood 2013; 121:1016 - 27; http://dx.doi.org/10.1182/blood-2012-07-445999; PMID: 23212522
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011; 144:601 - 13; http://dx.doi.org/10.1016/j.cell.2011.01.011; PMID: 21295337
   PubMed Web of Science ®Google Scholar
• Toe JG, Pellegrini M, Mak TW. Promoting immunity during chronic infection-The therapeutic potential of common gamma-chain cytokines. Mol Immunol 2013; 56:38 - 47; http://dx.doi.org/10.1016/j.molimm.2013.04.008; PMID: 23685259
   PubMed Web of Science ®Google Scholar
• Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334:98 - 101; http://dx.doi.org/10.1126/science.1209985; PMID: 21921156
   PubMed Web of Science ®Google Scholar
• Reardon C, Duncan GS, Brüstle A, Brenner D, Tusche MW, Olofsson PS, et al. Lymphocyte-derived ACh regulates local innate but not adaptive immunity. Proc Natl Acad Sci U S A 2013; 110:1410 - 5; http://dx.doi.org/10.1073/pnas.1221655110; PMID: 23297238
   PubMed Web of Science ®Google Scholar